166 related articles for article (PubMed ID: 23373966)
21. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
22. [Roles of the 2nd generation TKIs for CML].
Matsumura I
Rinsho Ketsueki; 2011 Oct; 52(10):1610-8. PubMed ID: 21971238
[No Abstract] [Full Text] [Related]
23. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
[TBL] [Abstract][Full Text] [Related]
24. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Shah NP; Guilhot F; Cortes JE; Schiffer CA; le Coutre P; Brümmendorf TH; Kantarjian HM; Hochhaus A; Rousselot P; Mohamed H; Healey D; Cunningham M; Saglio G
Blood; 2014 Apr; 123(15):2317-24. PubMed ID: 24569263
[TBL] [Abstract][Full Text] [Related]
26. Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Quintás-Cardama A; Jabbour EJ
Leuk Res; 2013 May; 37(5):487-95. PubMed ID: 23391518
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
29. Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Hampton T
JAMA; 2006 Jan; 295(4):369-70. PubMed ID: 16434621
[No Abstract] [Full Text] [Related]
30. Dasatinib is effective in imatinib-resistant CML.
Cannell E
Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
[No Abstract] [Full Text] [Related]
31. Chronic myeloid leukemia: advances in diagnosis and management.
Noronha S; Sawyer S
JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
[No Abstract] [Full Text] [Related]
32. Dasatinib: is it all in the dose?
Condorelli F; Genazzani AA
BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
[TBL] [Abstract][Full Text] [Related]
33. [Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia].
Klamová H
Vnitr Lek; 2013 Jul; 59(7):624-6. PubMed ID: 23909271
[TBL] [Abstract][Full Text] [Related]
34. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ
Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280
[TBL] [Abstract][Full Text] [Related]
35. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
36. Chronic myeloid leukemia. Introduction.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S2-3. PubMed ID: 18056928
[No Abstract] [Full Text] [Related]
37. [Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
Gómez Casares MT; León LG
Med Clin (Barc); 2013 Aug; 141(3):111-3. PubMed ID: 23462544
[No Abstract] [Full Text] [Related]
38. Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Cannella L; Breccia M; Stefanizzi C; Napoleone L; Santopietro M; Alimena G
Leuk Lymphoma; 2009 May; 50(5):848-50. PubMed ID: 19367499
[No Abstract] [Full Text] [Related]
39. Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
Allen-Bard S
Clin J Oncol Nurs; 2009 Oct; 13(5):537-42. PubMed ID: 19793710
[TBL] [Abstract][Full Text] [Related]
40. Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Breccia M; Alimena G
Leuk Res; 2011 Sep; 35(9):1153-5. PubMed ID: 21353701
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
